Showing 1 - 7 results of 7 for search 'Michael Guger', query time: 0.05s Refine Results
  1. 1
    Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria

    Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Au... by Michael Guger, Robert Hatschenberger, Fritz Leutmezer

    Published 2023-04-01
    Get full text
    Article
  2. 2
    Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry

    Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry by Michael Guger, Michael Guger, Gerhard Traxler, Martina Drabauer, Doris Leitner-Pohn, Christian Enzinger, Fritz Leutmezer, Dierk Oel, Franziska Di Pauli, Thomas Berger, Gerhard Ransmayr, Gerhard Ransmayr

    Published 2020-08-01
    Get full text
    Article
  3. 3
    Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria

    Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS st... by Michael Guger, Michael Matthias Ackerl, Martin Heine, Christiane Hofinger-Renner, Heinrich Karl Spiss, Andrea Taut, Karin Unger, Fritz Leutmezer

    Published 2022-06-01
    Get full text
    Article
  4. 4
    Cost-effectiveness of the Floodlight MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis

    Cost-effectiveness of the Floodlight MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis by Evelyn Walter, Matthäus Traunfellner, Franz Meyer, Christian Enzinger, Michael Guger, Christian Bsteh, Patrick Altmann, Harald Hegen, Christoph Goger, Veronika Mikl

    Published 2025-01-01
    Get full text
    Article
  5. 5
    Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study

    Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study by Thomas Seifert-Held, Katharina Eberhard, Christian Lechner, Christian Lechner, Stefan Macher, Harald Hegen, Tobias Moser, Gregor Brecl Jacob, Gertraud Puttinger, Raffi Topakian, Michael Guger, Emrah Kacar, Lea Zoche, Desiree De Simoni, Andreas Seiser, Stefan Oberndorfer, Christoph Baumgartner, Christoph Baumgartner, Christoph Baumgartner, Walter Struhal, Friedrich Zimprich, Johann Sellner, Florian Deisenhammer, Christian Enzinger, Markus Reindl, Helmut Rauschka, Helmut Rauschka, Thomas Berger, Romana Höftberger

    Published 2021-05-01
    Get full text
    Article
  6. 6
    Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people.

    Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. by Fahmy Aboul-Enein, Thomas Seifert-Held, Simone Mader, Bettina Kuenz, Andreas Lutterotti, Helmut Rauschka, Paulus Rommer, Fritz Leutmezer, Karl Vass, Agathe Flamm-Horak, Robert Stepansky, Wilfried Lang, Elisabeth Fertl, Thomas Schlager, Thomas Heller, Christian Eggers, Georg Safoschnik, Siegrid Fuchs, Jörg Kraus, Hamid Assar, Stefan Guggenberger, Martin Reisz, Peter Schnabl, Martina Komposch, Philipp Simschitz, Alena Skrobal, Alexander Moser, Mario Jeschow, Dorothea Stadlbauer, Manfred Freimüller, Michael Guger, Susanne Schmidegg, Claudia Franta, Vera Weiser, Stefan Koppi, Margret Niederkorn-Duft, Bettina Raber, Iris Schmeissner, Julia Jecel, Alexander Tinchon, Maria K Storch, Markus Reindl, Thomas Berger, Wolfgang Kristoferitsch

    Published 2013-01-01
    Get full text
    Article
  7. 7
    Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

    Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) by Heinz Wiendl, Ralf Gold, Thomas Berger, Tobias Derfuss, Ralf Linker, Mathias Mäurer, Orhan Aktas, Karl Baum, Martin Berghoff, Stefan Bittner, Andrew Chan, Adam Czaplinski, Florian Deisenhammer, Franziska Di Pauli, Renaud Du Pasquier, Christian Enzinger, Elisabeth Fertl, Achim Gass, Klaus Gehring, Claudio Gobbi, Norbert Goebels, Michael Guger, Aiden Haghikia, Hans-Peter Hartung, Fedor Heidenreich, Olaf Hoffmann, Boris Kallmann, Christoph Kleinschnitz, Luisa Klotz, Verena I. Leussink, Fritz Leutmezer, Volker Limmroth, Jan D. Lünemann, Andreas Lutterotti, Sven G. Meuth, Uta Meyding-Lamadé, Michael Platten, Peter Rieckmann, Stephan Schmidt, Hayrettin Tumani, Frank Weber, Martin S. Weber, Uwe K. Zettl, Tjalf Ziemssen, Frauke Zipp

    Published 2021-08-01
    Get full text
    Article

Search Tools: